ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1392

Comparing Data on Rheumatoid Arthritis (RA) Disease Status Using Patient Reported Outcome Measures (PROMS) RAID/RAPID-3/Self-Reported DAS28 in Remote Electronic Monitoring During the COVID-19 Pandemic with Face-To-Face Clinical Evaluation (DAS28-CRP) Performed Pre-Pandemic

Maria Mirza1, Kaiyang Song1, Madiha Ashraf2, Anushka Soni3, John Jackman3 and Raashid Luqmani1, 1Oxford University Hospital, Oxford, United Kingdom, 2Oxford Universtiy Hospital, Oxford, United Kingdom, 3Oxford University Hospital, Oxford, England, United Kingdom

Meeting: ACR Convergence 2022

Keywords: COVID-19, Disease Activity, Measurement, Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: During the COVID-19 pandemic, asynchronous consultations were introduced due to the significant backlog of patients with Rheumatoid arthritis awaiting clinical review. PROMs including Self-Reported Disease Activity Score-28 (SR-DAS28), Rheumatoid Arthritis Impact of Disease (RAID), Routine Assessment of Patient Index Data 3 (RAPID-3) and weighted RAPID-3 (RAPID-3 score divided by three) were assessed and compared with pre-pandemic clinician-assessed DAS28-CRP for the same patients. Furthermore, we evaluated whether moderate/high disease activity resulted in an appointment within three months, a measure of poor outcome.

Methods: We analysed the data pre-pandemic, from 01/01/2019-31/12/2020, and during pandemic from 01/11/2020-31/12/2021. During the pandemic, pre-clinic electronic surveys used for remote consultations were sent to patients. The data was passed into a secure database for calculation of PROMs. Statistical analysis comparing PROMs was performed using Pearson correlation coefficient.

Results: Out of 151 patients with RA, 72% reported moderate/high disease activity according to RAPID-3, whereas no patient was in remission (Figure 1). Notably, 16 out of 28 patients who were previously in remission according to pre-pandemic DAS28-CRP had moderate disease activity intra-pandemic. However, weighted RAPID-3 characterised 96.7% of patients as being in remission or having low disease activity (Figure 1). Disease activity according to RAID was more evenly distributed; 55% of the cohort exhibited moderate/high disease activity (Figure 1).

We showed a significant correlation between RAPID-3/weighted RAPID-3 and RAID (r=0.69, p< 0.001) (Figure 2); especially when RAPID-3 ≤15 (and weighted RAPID-3 ≤5) (r=0.84, p< 0.001). Self-Reported DAS28 did not correlate strongly with either RAID (r=0.22, p=0.0079) or RAPID-3 (r=0.21, p=0.013).

54% of patients with moderate/high disease activity according to RAID (n=83) and 49% according to RAPID-3 (n=110) required review within three months (Figure 3). Four out of five patients with moderate/high weighted RAPID-3 scores required a follow-up within three months (Figure 3).

Conclusion: RAID and RAPID-3 correlate particularly strongly at low disease activity. SR-DAS28 is not effective in indicating RA disease activity. RAPID-3 and weighted RAPID-3 skewed the cohort towards high disease activity and remission respectively. Conversely, RAID provides a more even distribution of patients across different disease activity statuses. Moderate to high weighted RAPID-3 scores were the best predictors for poor outcome (appointment within three months).

Supporting image 1

Figure 1: Disease activity of patients with Rheumatoid Arthritis according to pre-pandemic DAS28-CRP and intra-pandemic PROMS (SR-DAS28, RAPID_3, Weighted RAPID_3 and RAID)

Supporting image 2

Figure 2: Correlation between RAPID_3 and RAID in patients with Rheumatoid Arthritis during the pandemic

Supporting image 3

Figure 3: Requirement for appointments within three months for patients with moderate/high Rheumatoid Arthritis disease activity during the pandemic


Disclosures: M. Mirza, None; K. Song, None; M. Ashraf, None; A. Soni, UCB, Pfizer; J. Jackman, None; R. Luqmani, None.

To cite this abstract in AMA style:

Mirza M, Song K, Ashraf M, Soni A, Jackman J, Luqmani R. Comparing Data on Rheumatoid Arthritis (RA) Disease Status Using Patient Reported Outcome Measures (PROMS) RAID/RAPID-3/Self-Reported DAS28 in Remote Electronic Monitoring During the COVID-19 Pandemic with Face-To-Face Clinical Evaluation (DAS28-CRP) Performed Pre-Pandemic [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/comparing-data-on-rheumatoid-arthritis-ra-disease-status-using-patient-reported-outcome-measures-proms-raid-rapid-3-self-reported-das28-in-remote-electronic-monitoring-during-the-covid-19-pandemic/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparing-data-on-rheumatoid-arthritis-ra-disease-status-using-patient-reported-outcome-measures-proms-raid-rapid-3-self-reported-das28-in-remote-electronic-monitoring-during-the-covid-19-pandemic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology